Androgen Deprivation Therapy Market Insights On Growth Drivers, Trends, And Opportunities

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Androgen Deprivation Therapy Market Progress Between 2026 And 2030?

The market size for androgen deprivation therapy has experienced robust growth in recent years. This market is projected to expand from $8.31 billion in 2025 to $8.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. The expansion observed in the past can be linked to factors like the scarcity of treatment alternatives for prostate cancer, a prevalence of traditional surgery, the gradual uptake of injectable treatments, insufficient patient understanding of androgen deprivation therapy, and restricted access to sophisticated therapies.

The androgen deprivation therapy market is poised for significant expansion over the coming years. Projections indicate it will reach $11.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. This anticipated growth during the forecast period stems from factors such as the emergence of new anti-androgen medications, increased funding for gene and immunotherapies, a growing elderly male demographic, the proliferation of specialty clinics and hospital oncology units, and the incorporation of digital monitoring and telehealth services. Key developments expected in this timeframe involve a greater uptake of LHRH agonists and antagonists, a surge in the application of combination and targeted treatment approaches, the broadening scope of minimally invasive surgical techniques, an intensified emphasis on personalized and age-appropriate therapies, and improved monitoring and follow-up support for individuals with prostate cancer.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25692&type=smp

What Major Factors Are Driving The Androgen Deprivation Therapy Market Forward?

The rising prevalence of prostate cancer is anticipated to stimulate expansion within the androgen deprivation therapy market in future years. This cancer begins in the prostate gland, which is an organ in the male reproductive system tasked with producing seminal fluid. Its occurrence is increasing primarily because people are living longer, given that advanced age substantially elevates the likelihood of developing this condition. Androgen deprivation therapy (ADT) serves as a principal treatment approach for prostate cancer, designed to reduce androgen levels which promote tumor development. It is often employed in advanced or metastatic stages to slow down the disease’s advancement. For example, a January 2025 report from Prostate Cancer UK, a UK-based organization dedicated to prostate cancer research, awareness, and support, revealed that in England, prostate cancer diagnoses grew from 50,751 cases in 2022 to 55,033 cases in 2023. This clearly points to an upward trend in yearly incidence. Consequently, the growing occurrence of prostate cancer is propelling the expansion of the androgen deprivation therapy market.

Which Segment Types Are Examined In The Androgen Deprivation Therapy Market Segment Study?

The androgen deprivation therapy market covered in this report is segmented –

1) By Type: Medicine, Surgery, Other Types

2) By Route Of Administration: Injectable, Oral

3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75

4) By Application: Prostate Cancer, Other Applications

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies

2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy

3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU

What Trends Are Influencing The Androgen Deprivation Therapy Market?

Major companies operating within the androgen deprivation therapy (ADT) market are concentrating on developing sophisticated solutions, including oral androgen receptor inhibitors (ARIs), to provide more accessible, manageable, and efficacious treatment choices for individuals with prostate cancer. These oral ARIs are targeted therapies that directly impede androgen receptor activity in prostate cancer cells, thereby preventing tumor growth without requiring frequent clinic-administered hormone-suppressing injections. For instance, in June 2025, Bayer AG, a Germany-based multinational pharmaceutical company, received US Food and Drug Administration (FDA) approval for Nubeqa (darolutamide), an oral ARI used in combination with ADT for treating metastatic hormone-sensitive prostate cancer (mHSPC). Designed to improve clinical outcomes and patient quality of life, Nubeqa inhibits androgen receptor signaling with high binding affinity, demonstrates minimal blood–brain barrier penetration to limit central nervous system side effects, and showed a 46% reduction in the risk of radiological progression or death compared to placebo plus ADT, according to the Phase III ARANOTE trial.

Which Players Are Part Of The Competitive Landscape Of The Androgen Deprivation Therapy Market?

Major companies operating in the androgen deprivation therapy market are Johnson & Johnson Services Inc., Astellas Pharma Inc., Ipsen S.A., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Orion Corporation, Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Lawley Pharmaceuticals Pty Ltd., AbbVie Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Cipla Ltd., Accord Healthcare Ltd., Mylan N.V. (Viatris), Zydus Lifesciences Ltd., Apotex Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Alvogen Inc., BCN Peptides SA, Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd.

Get The Full Androgen Deprivation Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/androgen-deprivation-therapy-global-market-report

Where Is The Androgen Deprivation Therapy Market Most Concentrated Geographically?

North America was the largest region in the androgen deprivation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Androgen Deprivation Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/androgen-deprivation-therapy-global-market-report

Browse Through More Reports Similar to the Global Androgen Deprivation Therapy Market 2026, By The Business Research Company

Hormone Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Testosterone Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/testosterone-replacement-therapy-global-market-report

Drugs For Hormonal Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795